Active Not Recruiting PHASE1 INTERVENTIONAL 15-arm NCT03872947

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

Sponsor: Toray Industries, Inc

Conditions Bladder Cancer Cholangiocarcinoma Colorectal Cancer Epithelial Ovarian Cancer Fallopian Tube Cancer Gastric Cancer Melanoma Ovarian Cancer Palpable Subcutaneous Malignant Lesions Primary Peritoneal Cancer Renal Cell Carcinoma Solid Tumor

Interventions 5-FU Bevacizumab Carboplatin Cisplatin Gemcitabine Imiquimod Cream Irinotecan Leucovorin Nivolumab PLD Paclitaxel Pembrolizumab Ramucirumab TRK-950

Updated 21 times since 2019 Last updated: Jul 30, 2025 Started: Apr 26, 2019 Primary completion: Jun 30, 2026 Completion: Jun 30, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Bladder Cancer and Cholangiocarcinoma, this trial is ongoing. The trial is conducted by Toray Industries, Inc and has accumulated 21 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

21 versions recorded

Sep 2025 — Present [monthly]

Active Not Recruiting PHASE1
Jun 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1
May 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting
Sep 2024 — May 2025 [monthly]

Recruiting PHASE1
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1

▶ Show 16 earlier versions

Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Feb 2024 — Jun 2024 [monthly]

Recruiting PHASE1
Dec 2023 — Feb 2024 [monthly]

Recruiting PHASE1
Nov 2022 — Dec 2023 [monthly]

Recruiting PHASE1
May 2022 — Nov 2022 [monthly]

Recruiting PHASE1
Mar 2022 — May 2022 [monthly]

Recruiting PHASE1
Feb 2022 — Mar 2022 [monthly]

Recruiting PHASE1
Dec 2021 — Feb 2022 [monthly]

Recruiting PHASE1
Jan 2021 — Dec 2021 [monthly]

Recruiting PHASE1
Apr 2020 — Jan 2021 [monthly]

Recruiting PHASE1
Sep 2019 — Apr 2020 [monthly]

Recruiting PHASE1
Aug 2019 — Sep 2019 [monthly]

Recruiting PHASE1
Jul 2019 — Aug 2019 [monthly]

Recruiting PHASE1
Jun 2019 — Jul 2019 [monthly]

Recruiting PHASE1
May 2019 — Jun 2019 [monthly]

Recruiting PHASE1
Apr 2019 — May 2019 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Toray Industries, Inc

Data source: Toray Industries, Inc

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Dallas, United States , Eugene, United States , Fort Worth, United States , Leesburg, United States , Los Angeles, United States , Lyon, France , Milwaukee, United States , Morristown, United States , New Orleans, United States , New York, United States and 4 more locations